Scleroderma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Scleroderma, a connective tissue disorder, primarily manifests as thickened and hardened skin. There are two main types: localized and systemic, also known as systemic sclerosis. In localized scleroderma, the condition primarily affects the skin and may also impact muscles and bones. The exact causes of scleroderma remain unclear, but some evidence suggests genetic and environmental factors play a role in its development. Silica and specific organic solvents are recognized risk factors for systemic scleroderma. These factors trigger an immune system response, damaging blood vessels and tissues and forming scar tissue and excess collagen accumulation. Raynaud's phenomenon (RP) is often the initial symptom of scleroderma, sometimes appearing years before other signs of the disease. It is a visible expression of a systemic vascular issue fundamental to scleroderma's development. Three primary mechanisms contribute to scleroderma development: vascular anomalies, excess fibrosis, and autoimmune processes. Abnormal interactions between endothelial cells, fibroblasts, and lymphocytes (B and T) lead to microcirculatory vascular involvement. This results in the production of endothelin by endothelial cells, causing vasoconstriction and fibroblast activation. Additionally, fibroblasts and activated endothelial cells produce reactive oxygen species, accelerating vascular remodeling and the obliteration of small vessels. Activated fibroblasts quickly transform into myofibroblasts, which have an increased ability to synthesize collagen. Several other conditions exhibit skin changes similar to scleroderma, including Scleredema (scleredema diabeticorum and scleredema of Buschke), Eosinophilic fasciitis, Eosinophilia-myalgia syndrome, and Nephrogenic systemic fibrosis. The life expectancy of systemic sclerosis patients depends on the extent and severity of internal organ involvement. Compared to healthy individuals of the same age, those with SSc have a 3.5 times higher mortality rate. Survival rates for SSc patients are approximately 75-80% after five years, 55% after ten years, 35-40% after 15 years, and 25-30% after 20 years. Risk factors for higher mortality include older age at diagnosis, male gender, diffuse skin involvement, and organ involvement (such as pulmonary, cardiac, or renal). Systemic scleroderma's skin hardening and musculoskeletal effects, especially in the hands, can lead to functional disabilities. Oral restrictions can affect food intake and dental care. Linear scleroderma of the limbs, especially when it affects underlying bones, can also cause functional issues and potential aesthetic concerns in cases of "en coup de sabre" linear scleroderma. Treatment for scleroderma aims to alleviate symptoms and slow disease progression, although there is no single proven agent to modify the course of the disease.

·       Scleroderma is a rare disease, with an estimated prevalence of 276-300 cases per million in the United States.

 

Thelansis’s “Scleroderma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Scleroderma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Scleroderma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Scleroderma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Scleroderma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Scleroderma, Scleroderma market outlook, Scleroderma competitive landscape, Scleroderma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)